News
Sep 2023 NEW WODA MEMBER FOR AUSTRALIA, NEW ZEALAND AND SOUTHEAST ASIA World Orphan Drug Alliance Welcomes Specialised Therapeutics
Specialised Therapeutics to represent WODA in Australia, New Zealand and across Southeast Asia (ANZSEA)
Read more
Jun 2023 Improving PKU Management Relief Therapeutics and World Orphan Drug Alliance Announce an Exclusive, Long-Term, Distribution Agreement to Introduce PKU GOLIKE® in the Middle East
Companies join forces to introduce PKU GOLIKE Plus® 3-16, a breakthrough treatment for phenylketonuria (PKU), in the Middle East.
Read more
Mar 2023 Three new members – RareStone Group, CTS, and Path Pharma World Orphan Drug Alliance Expands to China, Israel, and Greece, Cyprus, and Malta
The addition of three new members – RareStone, CTS, and Path Pharma – brings the total number of countries covered by WODA to 76.
Read more
Jan 2023 The multi-territorial agreement covers 41 countries World Orphan Drug Alliance Announces Agreement with Theratechnologies for the Distribution of EGRIFTA SV®
A long-term, multi-territorial distribution agreement with Theratechnologies Inc. ("Theratechnologies") for EGRIFTA SV® covers 41 countries.
Read more
Nov 2022 WODA Alliance to Expand Access and Pricing Support World Orphan Drug Alliance – partnering with Decisive Consulting to broaden access capability
WODA Alliance partners with Decisive Consulting to enhance access & pricing support for rare diseases & specialized therapeutics globally.
Read more
Jun 2022 WODA covers 68 countries on 4 continents World Orphan Drug Alliance – combining forces to reach patients with rare diseases across the globe
EffRx, Medis, Orpharm, OrphanDC & Vector Pharma form World Orphan Drug Alliance to support rare disease & specialized therapeutics globally.
Read more